Technical Documentation
Other Information
Links to Other Datasets
PHOSP-COVID
The Post-hospitalisation COVID-19 study (PHOSP-COVID) is collaborating with the National COVID-19 Chest Imaging Database (NCCID). PHOSP-COVID is a national consortium, led by experts at the University Hospitals of Leicester NHS Trust under the umbrella of the NIHR Leicester Biomedical Research Centre. It aims to understand and improve long-term health outcomes for patients who have been discharged from hospital with confirmed or suspected COVID-19.
PHOSP-COVID has been set up and funded as a long term research study to recruit 10,000 patients who have been hospitalised with COVID-19. Over the course of a year, clinical assessments will track patients to gain a comprehensive picture of the impact COVID-19 has had on longer term health outcomes across the UK.
PHOSP-COVID will be collecting samples and scans for patients from a network of Trusts in the UK (see here for the full list).
PHOSP-COVID is collaborating with the NCCID initiative to ensure that the same sites included in the PHOSP-COVID network are also contributing towards the NCCID database. This is so that PHOSP-COVID researchers are able to access important data already collected for patients via the NCCID study in order to accompany the longitudinal data PHOSP-COVID are collecting for patients.
If you are contacted by the PHOSP-COVID study to upload data but are not yet contributing to the NCCID, we would ask that you follow the instructions here to ensure you are contributing to both studies.
ISARIC
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) was founded in 2011 to prevent illness and deaths from infectious disease outbreaks. It is a global federation of clinical research networks, providing a proficient, coordinated and agile research response to outbreak-prone infectious disease.
This consortium is responding to the current COVID-19 outbreak by creating tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments. One of these tools, the 'Clinical Characterisation Protocol' (CCP), has been co-developed by HDR UK members, in consultation with colleagues at the World Health Organisation.
The CCP sets out how data and biological samples from patients with COVID-19 should be collected, regardless of where in the world they are. It's the product of many years of discussion among international investigators from a wide range of scientific and medical disciplines. Work to develop this protocol started in response to Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) in 2012-2013, Influenza H7N9 in 2013, viral haemorrhagic fever (Ebolavirus) in 2014, Monkeypox & MERS-CoV in 2018 and Tick-borne encephalitis virus (TBEV) in 2019. It is now being used for COVID-19 .
ISARIC-4C will augment the aforementioned datasets, which have played a central role in the UK's research response to COVID-19, with imaging data from the NCCID. This will support improvements in the understanding, diagnosis and prognosis of the disease through the availability of data that comprises a wide range of variables such as clinical measurements, 'omics' assays, and radiology scans.